MetaVia Reports Adjusted Uric Acid Reduction of 1.47 mg/dL With DA-1726
Key Facts
MetaVia said on November 12, 2026, that its experimental treatment DA-1726 was associated with a placebo-adjusted reduction of 1.47 mg/dL in blood uric acid after 16 weeks in Part 3B of a Phase 1 trial. The company said the result was statistically significant at p<0.001, adding a metabolic measure to interim results it had previously reported for the drug. The analysis included 15 participants who received DA-1726 and four who received placebo, putting the sample size at the center of how the result should be read. On day 109, mean uric acid fell 1.02 mg/dL in the treatment group, from a baseline of 5.89 mg/dL. In the placebo group, the mean rose 0.45 mg/dL from a baseline of 4.80 mg/dL.
The company reported a 95% confidence interval for the adjusted reduction ranging from −2.0 to −0.9 mg/dL, with p<0.001 in the day 109 analysis. This measure compares the change between the treatment and placebo groups, while the unadjusted figures show each group’s trajectory from its own baseline. Chief Executive Hyung Heon Kim said participants “entered the study with mean levels in the normal range.” He added that elevated uric acid “has been associated with liver fat accumulation, insulin resistance and alcohol consumption,” linking the result to the company’s drug-development context. These associations provide background to the company’s interest in the measure, while the reported result remains a measure of uric acid change in a small interim analysis.
Part 3B is a 16-week, randomized, placebo-controlled study in adults with obesity whom the company described as otherwise healthy. Researchers escalated the DA-1726 dose weekly from 16 mg during the first four weeks to 32 mg during the next four weeks, then to the target dose of 64 mg. DA-1726 is an oxyntomodulin analogue that targets GLP-1 and glucagon receptors. MetaVia is developing it for cardiometabolic indications, including metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease. The study design and dosing context place the uric acid result within an early program testing the drug in people with obesity. Its development for the two liver disease groups is part of the company’s plans for a later study.
The uric acid result adds to a set of interim measures MetaVia previously announced from Part 3B. The company reported a placebo-adjusted reduction of 68.1% in liver fat and a similar reduction of 13.5% in weight, both statistically significant at p<0.001. It also recorded an absolute decrease of 0.44 percentage points in HbA1c, a measure of average blood sugar, at p=0.006. The company said all five participants who received DA-1726 and had hepatic steatosis at baseline reached an MRI-PDFF level below 5% by day 109. These figures present earlier interim results for weight, liver fat and blood sugar, while the November update adds uric acid to the reported measures.
MetaVia expects to publish full data from Parts 3A and 3B in the first quarter of 2027, according to its filing with the U.S. Securities and Exchange Commission. It also plans a 48-week, non-biopsy Phase 2 study involving up to 150 people with MetALD or ALD, with the study targeted to begin in the second half of 2027. The plan follows the early Part 3B results and expands the evaluation program to the liver disease patient groups identified by the company. Publication of the full data remains the nearest announced milestone ahead of the planned study. In trading on November 12, MetaVia shares, listed under the ticker MTVA, closed at $1.30, according to EL7 data.